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Stem Cell Research in California:  
The Intersection of Science, Politics, Culture, 
and Law 
 
Zach W. Hall* 
 
 In November 2004 the voters of California passed 
Proposition 71 (the California Stem Cell Research and Cures 
Bond Act), which authorized the expenditure of $3 billion for 
stem cell research raised through the issuance of state bonds.1  
The passage of Proposition 71 marked a new phase in 
American biomedical research.  For the first time, a state 
undertook to finance, through bonds, a large-scale biomedical 
research project in a new and untested area. 
Alive with scientific and medical possibility, stem cell 
research is nevertheless a new field whose effective application 
to human disease remains to be demonstrated.  The most 
promising facet of the new technology involves human 
embryonic stem cells, whose use in the United States is 
embroiled in ethical and political controversy rooted in the 
sensitive issue of abortion.2  Because of the controversy, the 
federal government has declined to support this research 
except on a limited basis,3 leaving California and other states 
to fill the gap.  Large, state-supported biomedical research 
projects offer an opportunity to develop new structures for 
funding biomedical science, but they also pose new challenges 
as inexperienced state governments struggle to establish 
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funding agencies and mechanisms.  In addition, the 
consequences of substituting a patchwork of state programs for 
strong central support from the federal government pose 
special problems for science administration. 
 Stem cell research in the United States touches the 
separate worlds of science, politics, ethics, law, and culture and 
brings them into an unusual juxtaposition, sometimes 
productively and sometimes not.  The California Institute for 
Regenerative Medicine (“CIRM”) established by Proposition 
71,4 now in its fourth year, has been involved in each of these 
realms.5  In view of the growing involvement of states in 
biomedical research, this article attempts to examine the 
California experience and determine what lessons can be 
learned.  Part I provides an overview of the science and 
importance of stem cell research; Part II discusses the 
development of current federal policies for oversight and 
funding of stem cell research; Part III discusses California’s 
Proposition 71; and Part IV concludes with lessons from the 
California experience. 
 
   I. THE IMPORTANCE OF STEM CELLS AND STEM CELL 
RESEARCH 
 
A.  THE UNDERLYING SCIENCE 
 
A brief summary of the early stages of human embryonic 
development is helpful in understanding the basis of stem cell 
research.  Fertilization of a mammalian oocyte, or egg, by a 
sperm results in successive rounds of cell division to produce a 
ball of about sixteen cells called the morula.  At this stage each 
of the roughly sixteen daughter cells, if separated from the 
others, can undergo successive divisions to form a new morula.  
Further cell divisions in the morula result in a more 
complicated structure, the blastocyst, a hollow sphere of 
                                                          
 4. Proposition 71 enacted an amendment to the California Constitution 
creating CIRM, amended a section of the California Government Code, and 
added sections to the Health and Safety Code.  See CAL. CONST. art. XXXV, § 
1; CAL. GOV’T CODE § 20069 (West 2004); California Stem Cell Research and 
Cures Act, CAL. HEALTH & SAFETY CODE §§ 125290.10–125291.85 (West 
2004). 
 5. See generally California Institute of Regenerative Medicine, 
http://www.cirm.ca.gov (last visited Sept. 27, 2008). 
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trophoblastic cells surrounding a fluid-filled cavity. Inside this 
liquid-filled cavity is a clump of 60–200 cells, attached to the 
wall on one side, which constitutes the inner cell mass.  The 
trophoblasts are responsible for subsequent attachment of the 
embryo to the uterine wall and the formation of the placenta; 
the inner cell mass differentiates and forms the more than 200 
different kinds of cells that make up the tissues of the body.6 
 The inner cell mass can be removed from the blastocyst 
and cultured as embryonic stem cells.7  It should be noted that 
in the absence of trophoblasts and uterine implantation, the 
cultured stem cells are unable to form an organized embryo.  
Instead, the cells divide robustly in culture to reproduce 
themselves and, under appropriate conditions, differentiate 
into the various cells of the body, such as nerve, muscle, skin, 
and blood.  The remarkable ability to self-renew through cell 
division, both in the embryo (in vivo) and in culture (in vitro), 
and the ability under appropriate conditions to produce any cell 
in the body, are the two defining features of embryonic stem 
cells and form the basis of their wide-ranging scientific and 
medical potential.8 
 During normal embryonic development, embryonic stem 
cells evolve along well-defined pathways to produce fully 
differentiated cells.  Differentiation is normally a one-way 
process; as cells become specialized, biochemical modification of 
the DNA, and of the proteins associated with it, alter the 
pattern of gene expression in a way that is appropriate for the 
differentiated cell.9  Muscle, skin, or thyroid cells, for example, 
each produce proteins that are specific for their respective 
functions. These cells remain specialized and do not normally 
replicate.  The differentiaton of stem cells into fully specialized 
cells does not occur in a single step, but along a pathway of 
intermediate cell types.  At each stage in the pathway, the 
capacity to self-renew and the potential to differentiate into 
other cells of the intermediates becomes more restricted.10  
Some of the later stage intermediates, called progenitor cells or 
                                                          
 6. See BRUCE M. CARLSON, HUMAN EMBRYOLOGY AND DEVELOPMENTAL 
BIOLOGY 43–44 (Inta Ozols & Joanie Milnes eds., 3d ed. 2004); KEITH L. 
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Gail R. Martin, Isolation of a Pluripotent Cell Line from Early Mouse Embryos 
Cultured in Medium Conditioned by Teratocarcinoma Stem Cells, 78 PROC. 
NAT’L ACAD. SCI. 7634, 7634–37 (1981). 
 8. National Institutes of Health, Stem Cell Information, 
http://stemcells.nih.gov/info/basics (last visited Oct. 14, 2008). 
 9. Rudolf Jaenisch & Richard Young, Stem Cells, the Molecular Circuitry 
of Pluripotency and Nuclear Reprogramming, 132 CELL 567, 567 (2008). 
 10. National Institutes of Health, supra note 8. 
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adult stem cells, remain in adult tissues in specialized sites 
called niches, where they can be activated to divide and 
produce the various cells of the tissue in which they reside, but 
not other cells.11  The adult stem cells in the bone marrow, for 
example, are responsible for maintaining circulating blood 
cells; it is these cells that replenish blood-forming capacity 
after a bone marrow or stem cell transplant.12  Consequently, 
adult stem cells may offer therapeutic possibilities in specific 
situations.  In contrast to embryonic stem cells, however, the 
therapeutic potential of adult stem cells is limited because of 
their small numbers, the difficulty of isolating and growing 
them, and the limited kinds of cells that they can produce.13 
 
B.  STEM CELLS AS THERAPEUTIC AGENTS AND SCIENTIFIC TOOLS 
 
The unlimited capacity of embryonic stem cells to self-
renew in culture to produce large numbers of cells, and their 
ability to differentiate into more specialized cells of various 
types are the bases of their potential use in cell replacement 
therapies.  In such therapies, specialized cells made in vitro 
from stem cells are introduced into the body to replace 
damaged or diseased cells.  Cell replacement therapy has 
potential applicability to a wide variety of ailments including 
diabetes, neurodegenerative disease, brain and spinal cord 
injury, and cardiovascular disease.14  Stem cell implantation 
can also be used as a means of delivering enzymes, growth 
factors, and other cellular products to discrete locations in the 
body.15  This can be accomplished by genetic manipulation of 
stem cells in culture to produce specific factors followed by 
injection of these stem cells into the needed sites, such as the 
brain, muscles, or joints.16 
Most of the human embryonic stem cell lines now available 
                                                          
 11. David T. Scadden, The Stem-Cell Niche as an Entity of Action, 441 
NATURE 1075, 1075–76 (2006). 
 12. David Bryder et al., Hematopoietic Stem Cells: The Paradigmatic 
Tissue-Specific Stem Cell, 169 AM. J. OF PATHOLOGY 338, 338 (2006). 
 13. Calvin B. Harley & Mahendra S. Rao,  Human Embryonic vs. Adult 
Stem Cells for Transplantation Therapies, in HUMAN EMBRYONIC STEM CELLS 
239, 239–43 (Arlene Y. Chiu & Mahendra S. Rao eds., 2003). 
 14. See generally National Institutes of Health, supra note 8. 
 15. Id. 
 16. Rahul Jandial et al., Genetic Modification of Neural Stem Cells, 16 
MOLECULAR THERAPY 450, 450–53 (2008). 
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were derived from excess embryos made for in vitro fertilization 
(“IVF”) and donated by couples for research and therapeutic 
purposes.17  To fully realize the potential of human embryonic 
stem cells, it would be advantageous to have cell lines, which 
are cells maintained in culture that are derived from a single 
source, from a variety of individuals of different genotypes.  
Human stem cell lines from those with an inherited disease 
would be particularly valuable for scientific purposes, as they 
could be used to investigate disease mechanisms and to identify 
new therapeutic targets for drug therapy. 
To more easily obtain human embryonic stem cell lines of 
particular genetic backgrounds, scientists have explored 
various ways of using adult cells to make cell lines with the 
properties of embryonic stem cells.18  In animals, such cells 
have been made by transferring the nucleus of an adult cell 
into an unfertilized oocyte whose own nucleus has been 
removed.  The cytoplasm in the oocyte effectively “reprograms” 
the adult DNA to erase the biochemical modifications that 
accompanied cell differentiation.19  The oocyte, containing the 
new DNA, is then induced to divide and form a blastocyst, 
whose genetic makeup is now identical, excluding the 
mitochondria, to the individual who donated the adult cell.20  
The inner cell mass of the blastocyst can then be isolated and 
stem cell lines can be made using conventional means. 
 Recently, scientists have been able to use gene transfer 
techniques to “reprogram” adult skin cells in both animals and 
humans, converting them into cells resembling embryonic stem 
cells.21  These induced pluripotent stem cells (“iPSCs”) are 
currently being intensively investigated as they offer great 
promise both for scientific investigation and possibly therapy, 
and they avoid many of the ethical issues associated with 
nuclear transfer into oocytes.  Umbilical cord blood and the 
                                                          
 17. James A. Thomson et al., Embryonic Stem Cell Lines Derived from 
Human Blastocysts, 282 SCI. MAG. 1145, 1145 (1998). 
 18. Megan J. Munsie et al., Isolation of Pluripotent Embryonic Stem Cells 
from Reprogrammed Adult Mouse Somatic Cell Nuclei, 10 CURRENT BIOLOGY 
989, 989–91 (2000). 
 19. Id. at 989. 
 20. Id. 
 21. See Rudolf Jaenisch & Richard Young, Stem Cells, the Molecular 
Circuitry of Pluripotency and Nuclear Reprogramming, 132 CELL 567, 567 
(2008); Nimet Maherali et al., Directly Reprogrammed Fibroblasts 
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CELL STEM CELL 55, 55–68 (2007); Kazutoshi Takahashi et al.,  Induction of 
Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors, 131 
CELL 1, 1–9 (2007); Kazutoshi Takahashi & Shinya Yamanaka, Induction of 
Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures 
by Defined Factors, 126 CELL 663, 663–73 (2006); Marius Wernig et al., In-
Vitro Reprogramming of Fibroblasts into a Pluripotent ES-Cell-Like State, 448 
NATURE 318, 318–23 (2007). 
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amniotic fluid surrounding the embryo may also contain cells 
that can be used for scientific or therapeutic purposes.22 
 
II. FEDERAL SUPPORT FOR STEM CELL RESEARCH 
 
The political and ethical issues that make stem cell 
research controversial have their roots in abortion politics, 
which for religious and other reasons has played a distinctive 
and important role in American cultural and political life.  
Because of the unwillingness of the federal government to 
engage these issues, research on human embryos in the United 
States has languished over the past thirty years.23 Most of the 
work done has occurred with private funding, both commercial 
and philanthropic, largely out of the public eye.24  With the 
legalization of abortion following Roe v. Wade in 1973,25 human 
fetal tissue was available for research for the first time, the 
ethical dimensions of which were addressed by the Belmont 
Report on Protection of Human Subjects of Biomedical and 
Behavioral Research.26  The Report, published in 1979, 
concluded that research on human fetal tissue was important 
for human health, but that the human fetuses, like other 
human subjects, had rights that deserved protection.27  To 
ensure this protection, the Belmont Report required that each 
proposal for federally-supported research on fetuses be 
approved by an Ethics Advisory Board.28  Before the Board 
approved and finalized any proposals, it was disbanded and not 
re-established.29  Human fetal tissue research was thus left in 
                                                          
 22. Ravindra Majeti et al., Identification of a Hierarchy of Multipotent 
Hematopoietic Progenitors in Human Cord Blood, 1 CELL STEM CELL 635, 
635–44 (2007); see generally David T. Harris & Ian Rogers, Umbilical Cord 
Blood: A Unique Source of Pluripotential Stem Cells for Regenerative 
Medicine, 2 CURRENT STEM CELL RES. & THERAPY 301 (2007). 
 23. STEPHEN S. HALL, MERCHANTS OF IMMORTALITY: CHASING THE 
DREAM OF HUMAN LIFE EXTENSION 97–122 (2003). 
 24. See id. 
 25. 410 U.S. 113 (1973). 
 26. See Hall, supra note 23, at 98–122. 
 27. NATIONAL COMMISSION FOR THE PROTECTION OF HUMAN SUBJECTS OF 
BIOMEDICAL AND BEHAVIORAL RESEARCH, BELMONT REPORT: ETHICAL 
PRINCIPLES AND GUIDELINES FOR THE PROTECTION OF HUMAN SUBJECTS OF 
RESEARCH, 44 Fed. Reg. 23,192–97 (Apr. 18, 1979). 
 28. Id. at 23,194–97. 
 29. According to Albert Jonsen, the Board was “summarily disbanded” by 
Patricia Harris, Secretary of Health, Education & Welfare in the Carter 
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a catch-22 situation, requiring approval by a body that did not 
exist.  This difficulty has not been resolved by subsequent 
administrations. 
 The political and ethical issues were further clouded by 
the success of IVF.  The first successful IVF procedure, 
resulting in the birth of a healthy baby, was carried out in the 
United Kingdom in July 197830 with little public fanfare and 
under no regulatory authority. Within a few years IVF 
technology was used successfully in other countries.  As this 
procedure grew into a world-wide industry, more than 100,000 
procedures were performed each year in the United States 
alone.31  With the success of IVF and its increasingly 
widespread use, the British government in 1990 established 
the Human Fertilisation and Embryology Authority as a 
regulatory agency to oversee all clinical and scientific use of 
human embryos.32  The United States government, however, 
was caught between a constituency of childless couples who 
embraced the new technology and those who viewed all 
manipulation of the human embryo as suspect and immoral, 
and simply avoided the issue.  Thus, the IVF industry, and now 
stem cell research, has developed in the United States without 
federal regulation. 
 The malaise and inaction of the federal government was 
overtaken by new scientific discoveries.  In 1982, Martin Evans 
in the United Kingdom and Gail Martin in the United States 
independently discovered mouse embryonic stem cells;33 in 
1996, Ian Wilmut in the United Kingdom extended IVF 
technology by using nuclear transfer techniques to clone 
Dolly;34 and in 1998, Jamie Thompson isolated the first human 
embryonic stem cells.35  Thompson’s work was supported by 
private, non-federal funds. 
These and other developments prompted two U.S. 
Congressmen, Representatives Roger Wicker of Mississippi and 
                                                          
administration.  Hall, supra note 23, at 101. 
 30. Robert G. Edwards et al., Establishing Full-Term Human Pregnancies 
Using Cleaving Embryos Grown In-Vitro, 87 BRIT. J. OBSTETRICS & 
GYNAECOLOGY 737, 750 (1980). 
 31. The Centers for Disease Control collects IVF information each year 
and publishes this data.  For 2005, over 134,000 cycles of IVF were reported 
by participating fertility clinics, resulting in 38,910 live births.  Department of 
Health and Human Services, Centers for Disease Control and Prevention, 
2005 Assisted Reproductive Technology Report, http://www.cdc.gov/art/ 
ART2005/section1.htm  (last visited Oct. 2, 2008). 
 32. Human Fertilisation and Embryology Act, 1990, c. 37, §5, sched. 1 
(Eng.). 
 33. Evans, supra note 7; Martin, supra note 7. 
 34. I. Wilmut et al., Viable Offspring Derived from Fetal and Adult 
Mammalian Cells, 385 NATURE 810, 810–12 (1997). 
 35. Thomson, supra note 17, at 1145–47. 
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Jay Dickey of Arkansas, to add an amendment to the 1996 
National Institutes of Health (NIH) appropriations bill that 
prohibited federal funding for work “in which a human embryo 
or embryos are destroyed, discarded, or knowingly subjected to 
risk of injury or death greater than that allowed for research on 
fetuses in utero.”36  This prohibition, now known as the Dickey 
Amendment, was continued in subsequent NIH budgets by 
inclusion in the Department of Health and Human Services 
appropriations bill.37  This was the beginning of federal human 
stem cell research policy, one that effectively removed the 
United States government from any role in funding or 
regulating the field. 
 In August 2001, in a dramatic, televised address to the 
nation, President George W. Bush declared that federal funds 
could be used for experiments on human stem cell lines, as long 
as the lines were derived prior to the date of the President’s 
address.38  Thus federal funds could not be used to derive new 
lines, but could be used for lines that had already been derived 
using non-federal funds.  To qualify for federal support, the 
lines had to be derived from unused blastocysts made for 
reproductive purposes.39  At the time, the President stated that 
there were more than sixty such lines that qualified for federal 
approval;40 subsequently, most have proved useless.  At present 
only twenty-one federally-approved lines exist,41 and only a 
handful are easily available; all were made with mouse feeder 
cells, raising the prospect that they have mouse antigens, and 
many have chromosomal rearrangements that are 
characteristic of tumor cells,42 thus making them unsuitable for 
therapeutic uses. 
President Bush deserves credit for permitting, for the first 
                                                          
 36. Pub. L. No. 106-554 § 510(a)(2), 114 Stat. 2763A-71 (2000). 
 37. Departments of Labor, Health and Human Services, and Education, 
and Related Agencies Appropriations Act, Pub. L. No. 107–116, § 510, 115 
Stat. 2177, 2219 (2002). 
 38. Press Release, White House Fact Sheet, supra note 3. 
 39. Id. 
 40. Id. 
 41. National Institutes of Health, Stem Cell Information, 
http://stemcells.nih.gov/staticresources/research/registry/PDFs/EligibilityCrite
ria.pdf (last visited Oct. 3, 2008) (indicating the twenty-one federally approved 
stem-cell lines that exist as of May 4, 2007). 
 42. Anirban Maitra et al., Genomic Alterations in Cultured Human 
Embryonic Stem Cells, 37 NATURE GENETICS 1099, 1099–1102 (2005). 
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time, federal funds to be used for human embryonic stem cell 
research.  But the severe limitations of the presidential policy  
have significantly truncated the development of this field in the 
United States, as acknowledged by Elias A. Zerhouni, the 
Director of NIH.43  Most seriously, the lack of federal support 
has discouraged bright and ambitious young scientists from 
entering what many see as an exciting new frontier in 
biomedical research.44 
 
III. CALIFORNIA’S STEM CELL INITIATIVE:     
PROPOSITION 71 
 
A.  THE INITIATIVE CAMPAIGN 
 
California’s answer to the federal restriction was 
Proposition 71, the California Stem Cell Research and Cures 
Bond Act.45  As early as 2002, California state legislators, led 
by State Senator Deborah Ortiz, introduced legislation to fund 
stem cell research in California.46  When the legislation failed 
to pass, Ortiz suggested that funding be obtained through an 
initiative, whereby voters pass judgment directly on legislative 
issues and bond measures.  Following a suggestion by Peter 
Van Etten, then CEO of the Juvenile Diabetes Research 
Foundation, Ortiz teamed with others, including a charismatic 
real estate development expert named Robert Klein, to mount a 
proposition campaign.  Klein rapidly became the dominant 
force, writing the proposition, directing the campaign, and 
raising more than $26 million to support it.  Klein, who has a 
son with Type I diabetes, had become involved with patient 
advocacy through the Juvenile Diabetes Research 
Foundation.47  For the ballot campaign a coalition was 
organized that included scientists, business leaders, politicians, 
and most importantly, a group of patient advocates, including 
Michael J. Fox and Christopher Reeve.48  The campaign was 
                                                          
 43. Mary Ann Akers, Going Against Bush, NIH Director Urges Expanded 
Stem Cell Research, WASH. POST, Oct. 17, 2007, at A15. 
 44. For example, on a trip in 2006, I met several young graduate students 
from California who had come to the United Kingdom to pursue graduate 
training in human embryonic stem cell research because adequate training 
was unavailable in the United States. 
 45. California Stem Cell Research and Cures Bond Act of 2004, CAL. 
HEALTH & SAFETY CODE §§ 125290.10– 125291.85 (West 2004). 
 46. S. 1272, 2001-2002 Leg., Reg. Sess. (Cal. 2002), available at 
http://www.leginfo.ca.gov/pub/01-02/bill/sen/sb_1251-
1300/sb_1272_bill_20020115_introduced.pdf. 
 47. CHRISTOPHER THOMAS SCOTT, STEM CELL NOW: FROM THE 
EXPERIMENT THAT SHOOK THE WORLD TO THE NEW POLITICS OF LIFE 171 
(2006). 
 48. Id. at 172–73. 
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waged as a full-scale political operation, including television 
advertisements, focus groups to sample public opinion, and an 
economic analysis that predicted a positive economic impact for 
the state from stem cell research.49  The campaign aggressively 
promoted the potential cures that might result.  For example, a 
video of spinal cord-injured rats walking after treatment with 
fetal stem cells was shown in support of the campaign.50 
On November 4, 2004, Proposition 71 passed with fifty-
nine percent of the vote51 at a time of fiscal difficulty for the 
State of California.  Post-election demographic analysis 
indicated that the Proposition received strong support across 
ethnic, gender, class, and geographical lines.52 
 The long and detailed ballot initiative, which included an 
amendment to the California Constitution, authorized the 
issuance of bonds totaling $295 million per year for ten years to 
support stem cell research at California institutions, prohibited 
funding for “reproductive cloning” to produce human beings, 
and established the California Institute for Regenerative 
Medicine (“CIRM”), its oversight board, the Independent 
Citizens Oversight Committee (“ICOC”), and three advisory 
working groups to implement the provisions of the measure.53  
Significantly, the Proposition also prohibited any modification 
of its terms by the legislature for three years and then only by 
a seventy percent margin in each house and with the consent of 
the governor.54  This strong barrier to modification has 
                                                          
 49. LAURENCE BAKER & BRUCE DEAL, ECONOMIC IMPACT ANALYSIS: 
PROPOSITION 71, CALIFORNIA STEM CELL 
RESEARCH AND CURES INITIATIVE 26–39 (2004). 
 50. Terri Somers, Proposition 71 Opens Tap for Stem-Cell Studies, SAN 
DIEGO UNION-TRIB., Oct. 8, 2004, at A1; see also SCOTT, supra note 48, at 184. 
 51. Carl T. Hall, Proposition 71: State Voters Strongly Backing Cell 
Research, S.F. CHRON., Nov. 3, 2004, at B4. 
 52. MARK BALDASSARE ET AL., MAKING HEALTH POLICY AT THE BALLOT 
BOX: CALIFORNIANS AND THE NOVEMBER 2004 ELECTION 14–15 (2005). 
 53. Proposition 71, Text of Proposed Laws, http://www.cirm.ca.gov/ 
pdf/prop71.pdf  (last visited Oct. 6, 2008); see also California Stem Cell 
Research and Cures Bond Act of 2004, CAL. HEALTH & SAFETY CODE §§ 
125290.10– 125291.85 (West 2004). 
 54. Proposition 71, Text of Proposed Laws, 
http://www.cirm.ca.gov/pdf/prop71.pdf  (last visited Oct. 6, 2008); see also 
LAURENCE BAKER & BRUCE DEAL, ANALYSIS OF THE FINANCIAL IMPACT ON 
THE CALIFORNIA STATE BUDGET OF THE PROPOSED CALIFORNIA INSTITUTE OF 
REGENERATIVE MEDICINE (2003), available at http://www.etopiamedia.net/ 
empnn/pdfs/baker2003.pdf, for an economic analysis of the Act on the state 
budget. 
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protected the stem cell research project in California from 
political interference, but has also made it difficult to modify 
the many detailed terms in the Proposition. 
 Proposition 71 has several notable features.  First, the 
idea of funding scientific research through the issuance of 
general obligation bonds is novel.  This financial mechanism 
provides stable long-term support, free from the vagaries of 
year-by-year political appropriations.  Viewed in these terms, 
the development of intellectual and scientific capital is treated, 
like schools, highways, and water systems, as a long-term 
investment in the state’s infrastructure.  This model of 
research financing has attracted attention both internationally 
and nationally.  Texas, for example, recently voted in favor of a 
$3 billion bond issue for cancer research.55  Second, in 
comparison to the NIH model, the Proposition gives 
considerable power to the ICOC relative to the CIRM, most 
notably in the executive responsibilities that are conveyed to 
the ICOC Chair.56  Third, as discussed below, Proposition 71 
gives patient advocates on the ICOC a powerful decision 
making role. 
 
B.  IMPLEMENTATION: STRUCTURE OF THE ICOC AND CIRM 
 
The ICOC, whose composition is specified by the 
Proposition, consists of twenty-seven  individuals, thirteen of 
whom are high-level administrators (e.g., deans, chancellors) of 
research institutions, four are from the private sector, and ten 
are patient advocates, plus a chair and vice-chair.57  The chair 
and vice-chair, Robert Klein and Ed Penhoet,58 respectively, 
are nominated by state officials and elected by the board.  All 
but five of the members are appointed by state officials within 
specific categories (i.e., by disease or type of institution). All 
members serve fixed terms of at least six years.  Surprisingly, 
there are no positions explicitly assigned to scientists, 
clinicians, bioethicists, or representatives of the public, and 
there are no provisions for removing ICOC members for 
                                                          
 55. H.R.J. Res. 90, 80th Leg., Reg. Sess. (Tex. 2007), available at 
http://www.legis.state.tx.us/tlodocs/80R/billtext/pdf/HJ00090F.pdf. 
 56. Transcript of Regular Meeting Before the Independent Citizens’ 
Oversight Committee to the California Institute for Regenerative Medicine 
Organized Pursuant to the California Stem Cell Research and Cures Act at 
139–73 (2006), available at http://www.cirm.ca.gov/transcripts/pdf/2006/06-02-
06.pdf. 
 57. California Institute of Regenerative Medicine, Independent Citizens 
Oversight Committee List of the California Institute for Regenerative 
Medicine, http://www.cirm.ca.gov/faq/pdf/Members.pdf  (last visited Oct. 3, 
2008). 
 58. Id. 
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cause.59 
The initiative limits CIRM, which is responsible for 
administering the grants, to a staff of fifty, and its budget for 
the life of the enterprise is limited to six percent of the $3 
billion in total bond proceeds.60  The current CIRM president is 
Dr. Alan Trounson, a prominent reproductive biologist from 
Australia.61 
 Further, Proposition 71 provides for the establishment of 
three advisory working groups. The Grant Working Group is 
devoted to research grant evaluation and is composed of 
scientists from outside California and patient advocates from 
the ICOC. The Ethics Working Group develops 
recommendations for medical and ethical standards and is 
composed of ethicists, scientists, and patient advocates from 
the ICOC.  The Facilities Working Group provides 
recommendations for facilities funding and is composed of real 
estate experts and patient advocates from the ICOC.62  The 
Proposition allows up to ten percent of the $3 billion to be spent 
for the construction of new research facilities of non-profit 
institutions.63  All final decisions on funding and policy are 
made by the ICOC.  CIRM staff do not make recommendations 
on ethical matters or funding decisions, but they are 
responsible for overseeing the process.  Patient advocates are 
the only representatives from the ICOC who are on the 
working groups.  Because there are only ten, all serve on one or 
two working groups; some are on all three, requiring a 
tremendous commitment of time and effort.  Each working 
group has either a co-chair or vice-chair who is a patient 
advocate. 
 The prominent role of the patient advocates in guiding 
the stem cell project is unusual and reflects, in part, the 
influential role that they played during the campaign, which 
was supported by over seventy disease groups, including the 
Christopher Reeve Paralysis Foundation, Parkinson’s Action 
                                                          
 59. California Stem Cell Research and Cures Act, CAL. HEALTH & SAFETY 
CODE §§ 125290.20 (West 2004). 
 60. Id. §§ 125290.45, 125290.70. 
 61. California Institute of Regenerative Medicine, Leadership, 
http://www.cirm.ca.gov/info/leadership.asp (last visited Oct. 3, 2008). 
 62. California Stem Cell Research and Cures Act, CAL. HEALTH & SAFETY 
CODE  § 125290.50 (West 2004). 
 63. Id. § 125290.70(a)(4). 
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Network, Project ALS and the Juvenile Diabetes Foundation 
among others.  The role of the patient advocates in the project 
is critical, as they focus attention on the ultimate goal, which is 
to treat disease.  Their expectations and mode of operation, 
however, have sometimes been at odds with the scientific and 
academic members of the ICOC.  As addressed below, bridging 
this gap has been one of the important issues that the ICOC 
has dealt with. 
 
C.  INITIAL CHALLENGES 
 
 At its inception, CIRM and its oversight board, the ICOC, 
faced at least four major challenges.  First, the defining 
scientific mission of CIRM was formidable: to develop disease 
therapies based on a new and untested technology at the 
frontier of modern science.64  Human embryonic stem cells were 
first described only ten years ago,65 and even now there is 
much that scientists do not understand about them.  Moreover, 
to bring any therapy to the stage of clinical use is a long and 
expensive process with a high rate of attrition.66  To achieve its 
goals, CIRM developed a comprehensive plan, the Scientific 
Strategic Plan, to guide its efforts over the life of the project.67  
During the first two years, CIRM implemented this plan by 
awarding more than $200 million in funds for research and 
education.  Because of these grants, research on human 
embryonic stem cells is now underway in more than 100 
laboratories in non-profit research institutions throughout 
California.68 
 Second, CIRM had to establish a new granting agency in 
its early years.  CIRM developed policies to ensure that the 
research it funds is carried out according to the highest medical 
and ethical standards, that awards are made based on merit 
and without bias, and that both financial accountability and a 
financial return to the state, where appropriate, exist.  After 
                                                          
 64. Arlene Y. Chiu & Zach W. Hall, Stem Cell Research: The California 
Experience, 26 J. NEUROSCI. 6661, 6662 (2006). 
 65. See generally Thomson et al., supra note 17 (discussing the possibility 
of  human stem cells lines in 1998). 
 66. Joseph A. DiMasi, Risks in New Drug Development: Approval Success 
Rates for Investigational Drugs, 69 CLINICAL PHARMACOLOGY & 
THERAPEUTICS 297, 297 (2001); Joseph A. DiMasi et al., The Price of 
Innovation: New Estimates of Drug Development Costs, 22 J. HEALTH ECON. 
151, 180–83 (2003). 
 67. California Institute of Regenerative Medicine, CIRM, 
http://www.cirm.ca.gov/meetings/pdf/2006/12/120706_item_7.pdf  (last visited 
Oct. 10, 2008). 
 68. California Institute of Regenerative Medicine, CIRM: Approved CIRM 
Grants as of June 2008, http://www.cirm.ca.gov/info/grants.asp (last visited 
Oct. 3, 2008). 
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extensive discussion and public input, CIRM adopted 
appropriate policies and procedures in these areas.69 
Third, CIRM was a new state government agency, which 
had to be established from the ground up.  Rigorous conflict-of-
interest policies were established, and, in accordance with the 
California Administrative Procedure Act,70 all of the proposed 
policies were examined by the state with a formal period of 
public comment and response until they became formal 
regulations with the power and effect of state law. 
 Fourth, litigation that was almost immediately brought 
against CIRM complicated its ability to accomplish other goals 
during the first two years.71  Although the lawsuits were based 
on constitutional grounds, the organizations that brought suit 
represented or were funded by the religious right.72  The suits 
were eventually found to be completely without merit,73 but 
during the litigation and appeals — lasting about eighteen 
months — CIRM was unable to raise bond money, leaving both 
operating and grant funds severely limited.  Short-term loans 
totaling $45 million from philanthropic individuals and 
foundations, plus a loan of $150 million from the state,74 
allowed CIRM to fund the grants described above.  In October 
2007, the state issued the first tranche of bonds, worth $250 
million, for stem cell research.75 
 
                                                          
 69. See California Institute of Regenerative Medicine, CIRM Policies, 
http://www.cirm.ca.gov/policy/policy.asp (last visited May 12, 2008); see also 
California Institute of Regenerative Medicine, Adopted CIRM Regulations, 
http://www.cirm.ca.gov/reg/default.asp (last visited Oct. 3, 2008). 
 70. California Administrative Procedure Act, CAL. GOV’T CODE §§ 11340–
11365 (2007). 
 71. Cal. Family Bioethics Council v. Cal. Inst. for Regenerative Medicine, 
55 Cal. Rptr. 3d 272, 312 (Cal. Ct. App. 2007); see Doe v. Klein II, No. 5:2005-
cv-00438-RSWL-SGL (C.D. Cal. 2005), aff’d, 254 Fed.Appx. 626 (9th Cir. 
2007). 
 72. See Stem-cell Institute Gets $5 Million Gift, SACRAMENTO BUS. J., 
June 7, 2005, available at http://eastbay.bizjournals.com/sacramento/stories/ 
2005/06/06/daily15.html. 
 73. Cal. Family Bioethics Council, 55 Cal. Rptr. at 312 (affirming the 
lower court decision finding no constitutional issue or legal infirmity with 
Proposition 71); Doe, 254 Fed.Appx. at 629 (granting defendant’s motion to 
dismiss for improper venue), cert. denied, 128 S.Ct. 1751 (2008). 
 74. CAL. INST. FOR REGENERATIVE MED., CAL. INST. FOR REGENERATIVE 
MED. ANN. REP. 2007 at 5, available at http://www.cirm.ca.gov/ 
press/pdf/annual_rpt.pdf. 
 75. Id. at 30. 
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IV. LESSONS FROM THE CALIFORNIA EXPERIENCE 
 
 One striking aspect of the California stem cell project 
has been the strong degree of public interest that it evoked.  
The fascination of the public with CIRM is partially grounded 
in the deep hopes that stem cell research inspires and the belief 
that California is in the vanguard in bringing this important 
new scientific area to therapeutic fruition.  The project also 
attracted the intense attention of the press, state politicians, 
and public interest representatives, particularly in its early 
years.76 Although not elected or accountable in any real sense, 
these public interest representatives receive attention, 
sometimes an excessive amount, from the press.  Fortunately, 
most are responsible and well-meaning critics who support 
stem cell research, but also want the agency to represent the 
highest standards of accountability, transparency, and 
responsibility to the public. 
 Critics outside of the courtroom have been mostly from 
the left, focusing on issues of transparency, conflict-of-interest, 
egg donation, and access for all Californians to stem cell 
therapies developed by CIRM funding.  Many of these issues 
have revealed a deep gulf between scientific and political 
cultures at the state level.  For example, politicians sometimes 
do not understand the advantages of confidential peer review, 
which Proposition 71 protects, and to which CIRM has adhered.  
Likewise, scientists are unaccustomed to the strong “sunshine 
laws” of California that require all meetings of state bodies, 
with certain narrow exceptions written into Proposition 71, to 
be public meetings and that the public be allowed input before 
decisions are reached.  The extensive involvement of the public 
in all aspects of the development of CIRM policies, scientific 
and otherwise, has been time-consuming and often tedious, but 
has been necessary to gain public confidence.  The public’s 
participation in CIRM’s decision-making process strengthened 
the decisions.  As a public agency, CIRM must be accountable 
to the public and to the legislature, and must work to earn the 
confidence of both. 
 A striking and related feature of the CIRM experience is 
the powerful role of patient advocates.  The increased role of 
the public and particularly of patient advocates in making 
decisions about scientific policy and direction is not unique to 
California.  “Advocates want a say in the way biomedical 
                                                          
 76. In July 2005, the first six months after the creation of CIRM, a count 
of news stories covering CIRM conducted by Edelman (a public relations firm)  
totaled 2,481 (921 from January 1-April 6, 2005; 1,560 from April 7-July 22, 
2005).  Email from N. Pagano, former Communications Officer, CIRM to Dr. 
Zach Hall, former president of CIRM (Apr. 14, 2008) (on file with the author). 
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research is conducted.”77  The inclusion of patient advocates 
brings a sense of urgency and zeal to biomedical research that 
makes its relevance clear, and it is an important component of 
earning public support.  Patient advocates also bring an 
intimate knowledge of disease and its effects on patients and 
their families that scientists often lack, and they keep the 
scientific community focused on the aim of curing disease. 
The perspectives of science and patient advocacy, although 
in many ways complementary, are often not aligned.  Scientists 
are generally focused on questions of mechanism and 
understanding, whereas patients are focused on immediate 
cures.  Both aims are necessary for success and, in a 
cooperative way, both can be achieved. 
A third feature of the California experience is the conflict 
of interest issue, arising from the composition of the ICOC.  
The largest group on the board consists of leaders of research 
institutions that are grantees of CIRM.  The resulting conflict 
of interest is easily managed when the ICOC considers grants 
to individual researchers, as members simply abstain from 
discussing and voting on grants to their institution.  On other 
issues, such as an appropriate level of indirect cost returns, all 
of the institutional leaders have a large financial stake in the 
outcome.  The issue arises again in considering funding for 
facilities, as each of the institutions competes against others for 
limited funds.  CIRM lawyers have determined that in this 
situation, all institutional leaders have a conflict of interest for 
each application, because the success of one diminishes the 
chances of success for others.78  The final decision awarding 
$271 million for facilities, the largest single expenditure to date 
by CIRM, was decided by only seven members out of the 29 
positions on the ICOC, the only ones who as patient advocates 
or members of the private sector had no institutional conflict of 
interest.79  A poor understanding of conflict of interest issues 
and difficulty in separating the respective roles of being a 
member of the ICOC and of being an institutional leader has 
                                                          
 77. REBECCA DRESSER, WHEN SCIENCE OFFERS SALVATION: PATIENT 
ADVOCACY AND RESEARCH ETHICS 23 (2001). 
 78. California Stem Cell Report, Zipped Lips and CIRM’s $263 Million, 
http://californiastemcellreport.blogspot.com/2008/01/zipped-lips-and-cirms-
263-million.html (last visited Oct. 14, 2008). 
 79. John M. Simpson, Stem Cell Agency’s Conflicted Board, 
http://www.consumerwatchdog.org/patients/articles/?Story Id+20122 (last 
visited Oct. 10, 2008). 
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also recently created significant legal and political problems for 
the ICOC.80 
 For the expanding role of patient advocates and public 
members in the scientific enterprise to be successful, 
recognition of the distinct perspectives of constituents and a 
continuing effort to build trust and understanding are 
necessary.  Time, energy, and a willingness to change one’s 
point of view are also necessary.  As not all members of the 
various communities are equally suited to or interested in this 
task, it becomes important that those who are appointed to 
decision-making positions have, in addition to other 
qualifications, respect for, and the ability to work with, 
members of the other constituencies. 
Having a broader range of ideas among those involved in 
making decisions requires developing new structures and 
procedures.  The most successful structures will be those that 
include all parties in the deliberations and that respect the 
areas of expertise of each.  Patient advocates best represent the 
needs of the patient community; scientists are best-equipped to 
determine directions of scientific strategy; ethicists clarify the 
moral and ethical questions; and representatives of the public 
recognize the responsibilities to the larger community.   As the 
group of decision-makers broadens, the extent to which values 
are shared about how decisions are made will diminish. This 
requires a more conscious attempt to think about both conflicts 
of interest and how decisions can be made not only effectively, 
but also fairly and without bias. 
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